Literature DB >> 26239624

Clinicopathological and immunohistochemical characteristics of papillary renal cell carcinoma with emphasis on subtyping.

Ahmed K Alomari1, Oluwarotimi S Nettey2, Dinesh Singh2, Harriet Kluger3, Adebowale J Adeniran4.   

Abstract

Papillary renal cell carcinoma (PRCC), a morphologically and genetically distinct subtype of RCC, is morphologically separated into 2 subtypes for therapeutic and prognostic purposes. Type 2 tumors are generally believed to have a poorer prognosis than type 1 tumors. In spite of multiple studies, many clinicopathological issues about PRCC remain vague. We studied the clinicopathological features associated with type 1 versus type 2 PRCC, and we compared the immunohistochemical profiles in both subtypes of PRCC. We identified a total of 144 cases (74 type 1, 46 type 2, and 24 mixed), 29 female and 115 male. Mean age was 56 years for type 1 and 59 years for type 2. Mean tumor size was 3.6 cm for type 1 and 4.6 cm for type 2. Type 1 tumors were more likely to have nuclear grade 2 and less, whereas type 2 tumors were more likely to have nuclear grade 3 and above (P = .0001). There was no significant association between tumor type and renal sinus fat invasion, invasion of muscular branches of renal vein, perinephric fat invasion, microvascular angiolymphatic invasion, and main renal vein invasion. Type 2 tumors have higher nuclear grades than type 1 tumors. Based on long follow-up data, both subtypes appear to have excellent prognosis when diagnosed at early stage. The immunohistochemical profiles of both types 1 and 2 PRCC are essentially the same. The similar immunohistochemical profile suggests that PRCC is one entity with divergent histologic features.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Histology; Immunohistochemistry; Morphology; Papillary renal cell carcinoma; Subtyping; Tumor; Type 1 and type 2

Mesh:

Substances:

Year:  2015        PMID: 26239624     DOI: 10.1016/j.humpath.2015.06.006

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Papillary Renal Cell Carcinomas Demonstrating Micropapillary Features: An Investigation Into the Diagnostic and Prognostic Implications.

Authors:  Beatriz Caraballo; Maha Abdulla; Sunder Sham; Guang-Qian Xiao; Pamela Unger
Journal:  Cureus       Date:  2022-05-12

Review 2.  Prognostic factors and prognostic models for renal cell carcinoma: a literature review.

Authors:  Tobias Klatte; Sabrina H Rossi; Grant D Stewart
Journal:  World J Urol       Date:  2018-04-30       Impact factor: 4.226

3.  Identification of 4-genes model in papillary renal cell tumor microenvironment based on comprehensive analysis.

Authors:  Liang Luo; Haiyi Zhou; Hao Su
Journal:  BMC Cancer       Date:  2021-05-17       Impact factor: 4.430

4.  Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.

Authors:  Nina Wagener; Dominic Edelmann; Axel Benner; Richard Zigeuner; Hendrik Borgmann; Ingmar Wolff; Laura M Krabbe; Mireia Musquera; Paolo Dell'Oglio; Umberto Capitanio; Tobias Klatte; Luca Cindolo; Matthias May; Sabine D Brookman-May
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

5.  A Novel Ferroptosis-Related lncRNA Signature for Prognosis Prediction in Patients with Papillary Renal Cell Carcinoma.

Authors:  Ruijie Dang; Meiling Jin; Jingzhu Nan; Xuege Jiang; Zheng He; Fang Su; Diangeng Li
Journal:  Int J Gen Med       Date:  2022-01-06

6.  Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Shengwei Xiong; Weijie Zhu; Xinfei Li; Yanfei Yu; Kunlin Yang; Lei Zhang; Yue Mi; Xuesong Li; Liqun Zhou
Journal:  Transl Androl Urol       Date:  2021-08

7.  Prognostic Effect of Subclassification on Oncological Outcomes in Patients with Surgically Treated Localized Papillary Renal Cell Carcinoma: A Retrospective Propensity Score-matched Cohort Study.

Authors:  Shijie Li; Xuefeng Liu; Xiaonan Chen
Journal:  J Cancer       Date:  2022-01-16       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.